Replies to post #102167 on Amarin Corp Plc (AMRN)

[Whalatane]

PY can you link the " interesting development today with the Epanova label " thx

From memory Epanova violates some of AMRN's composition patents .

Re energy stocks ...will be capped by US shale oil ...Shale co's ramp up whenever price is above $50 a barrel. Exxon planning huge expansion in Shale ...more supply
FYI
https://www.bloomberg.com/news/articles/2017-03-10/race-to-bottom-on-costs-may-cause-oil-to-choke-on-own-supplies

Just my quick take
kiwi

[Bolio98]

Even docs just don't look deep enough much of the time. They're simply too busy.

Yeah that's probably it. Why would they bother with any anecdotal evidence if they change a prescription from Lovaza to Vascepa. Why would they put a new patient on Vascepa rather than Lovaza. Probably just a lot of physicians rolling the dice out there.

Or of course the obvious, more and more cardiologists are investing in AMRN and they want the SP to rise.

[jessellivermore]

Ah yes ...Lipidolgists...

True story...A couple of years a go I went to dinner sponsored by Amarin at Shula's (a great restaurant in Lake Mary right outside of Orlando)..The speaker (paid by Amarin) was a lipidologist... What a dumb ass. He did not have the foggyist command of the clinical or scientific literature and I had to correct him about ten times..This guy was still recommending niacin and fibrates for trig lowering.

Lipidologists are why the whole CVD field is in such shambles..Quote " their (Amarin's) entire marketing plan depends on a fallacy that any lipidologist understands but sadly few internists appreciate"..Yes the internists and apparently the FDA doesn't understand what these brainy lipidologists do and that is why Lovaza never got the green light from the FDA for CVD..Also this brainiac that PYR abides by does not seem to know that L increases your risk for A fib.

The other thing that none of the dinosaur lipidologist know is that EPA has pleotropic effects including the fact EPA lowers systemic inflammation. Something no lipidologist knows is that atherosclerosise is an inflammatory disease and not a lipid disorder.

":>) JL

[HDGabor]

P-

Interesting development today with the Epanova label. Could be bearish.

LMAO ...
- you do not know any details about it
- sNDA 003 was immaterial
- support wyour view with BB's post ... who does not have a clue about the date today ...

Generics coming in 2020 for Vascepa btw.. will be tough to stop them

FDA could not approve (as final approval) generics if the case will be still ongoing, they could give conditional approval only. If Amarin will win the patent case (more likely, see below AZN case) generic could not be sold ...

That was dismissed if I'm not mistaken. ... Perhaps they delayed the launch because they were after 5 year exclusivity. Maybe they just got it from FDA. Either way there is a new label for Epanova. And maybe they'll launch soon.

Yes, it was dismissed ... because AZN (not Amarin) requested it ... and AZN has to inform AMRN before the launch of Epanova. NCE was granted for Epanova, but nearly 3 yrs after approval (May 2014) it is not on the market ... guess why? ... btw: V did not delay the launch despite lack of NCE ... since NCE does have any relation with sales.

Think a moment: why AZN requested dismissal, instead of force the case and win (?) the case / eliminate AMRN patent(s) ...

Don't cite your recent post as a support of your "Fund" ... btw: it was the funniest cover story I heard ever :-)

Best,
G